- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
David Alain Wohl, MD, Discusses Strategies to Improve HIV Management
David Alain Wohl, MD, associate professor, division of infectious diseases, University of North Carolina at Chapel Hill, suggests that quality management of HIV has, for the most part, been self-regulated. He says that when it comes to HIV management, there is a lack of feedback or "quality improvement mechanisms" outside the managed care setting.
David Alain Wohl, MD, associate professor, division of infectious diseases, University of North Carolina at Chapel Hill, suggests that quality management of HIV has, for the most part, been self-regulated. He says that when it comes to HIV management, there is a lack of feedback or “quality improvement mechanisms” outside the managed care setting.
While many managed care organizations provide metrics for practitioners, Dr Wohl says that feedback varies greatly depending upon a given system. The benefit of HIV management is that providers know exactly which types of guideline-based metrics to employ that work to combat those variations.
“We know what we’re supposed to do. We know that people are supposed to be started on HIV medicine, certainly at certain CD4 cell counts, if not everyone,” Dr Wohl says. “We know about vaccines, we know about cancer screening. There’s a bunch of stuff that we exactly know where the x’s in the box and that we should be doing it, so it lends itself to quality improvement measures.”
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
